Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...

Genetic testing for cardiovascular disorders is rapidly expanding, including among children. In its first scientific statement focused on the issue of cardiovascular genetic testing specifically among ...

Cardiovascular genetic testing in children presents unique challenges, requiring pre- and post-test counseling with an individualized approach for families, ideally with the involvement of a ...

Cardiovascular testing is a $7.8 billion market, yet for about 30% of patients, their first indication of cardiovascular disease is death, according to the nomination. Myeloperoxidase (MPO), a white ...

The results of a recent retrospective analysis of electronic health record (EHR) data found that only 0.4% of patients with atherosclerotic cardiovascular disease (ASCVD) were tested for lipoprotein(a ...

Early diagnosis and treatment can contribute to saving or improving people's lives and could help healthcare systems save money Basel, 28 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced a ...

It is widely known that cardiovascular diseases (CVD) are one of the leading causes of death. In India, recently the disease burden has been shifting from ...

Dennis R. Leahy, MD, shares his POV on the value of making Lp(a) testing universal, not only to inform patients and their clinicians of the high CV risks, but to make way for potential treatments.

Cardiovascular diagnostic market was valued at $6,876.29 million in 2020, and is projected to reach $15,430.46 million by 2030, registering a CAGR of 8.3% from 2021 to 2030. Cardiovascular diseases ...